mar feb jan dec nov oct sep fda drugs january vynase vyvanse gets approvable letter new river pharm shire poised release new adhd drug lisdexamfetamine nrp generic wellbutrin xl approved anchen pharma wellbutrin package insert modified reflect following additional info regarding use people renal failure inter study comparison normal subjects patients end stage renal failure demonstrated parent drug cmax auc values comparable groups whereas hydroxybupropion threohydrobupropion metabolites fold increase respectively auc patients end stage renal failure also added mention double vision increased intraocular pressure reported adverse reactions fda releases guidance pharmacogenetic data fda released definitions genomic biomarkers pharmacogenomics pharmacogenetics alexza working schizophrenia agitation drug drug inhaled form loxapine typical antipsychotic new antidepressant pristiq wyeth makes effexor xr venlafaxine received approvable letter pristiq desvenlafaxine succinate metabolic derivative effexor drugs serotonin norepinephrine reuptake inhibitors snris approvable letters conditions must met product marketed wyeth facility puerto rico must pass fda muster marketing plan must approved prior release major depression indication wyeth also going indication vaso motor symptoms vms related menopause hot flashes english